16 September 2026 note archive · Item
Minutia (gene-edited hypoimmune islets + graft nanosensors): review notes
These archived notes document the scope reviewed on 16 September, including source-access limits. They do not cover later changes or newly added records. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: corrected/updated. Current item
lastReviewed: 2026-08-27. - Claim check: Minutia's CIRM/NIH awards and preclinical descriptions are funding and design evidence, not clinical efficacy. Removed exclusive-human-benchmark wording. No IND or trial was located; unsuccessful searches are not proof of worldwide absence.
- Primary publication/regulatory sources checked or consulted: NEJMc2604408.
- Programme/sponsor/conference source boundary: Minutia | A Next Generation Cell Therapy Company (manufacturer); Bioengineering human stem cell-derived beta cell organoids to monitor cell health in real time and improve therapeutic outcomes in patients (CIRM DISC2-13498) (registry).